| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
4183 Stock Overview
EPS Bio Technology Corp. manufactures and sells OEM/ODM glucose meters and strips primarily in Taiwan.
EPS Bio Technology Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$18.50 |
| 52 Week High | NT$20.90 |
| 52 Week Low | NT$17.60 |
| Beta | 0.65 |
| 1 Month Change | 0.82% |
| 3 Month Change | 1.93% |
| 1 Year Change | -7.73% |
| 3 Year Change | 3.93% |
| 5 Year Change | -23.08% |
| Change since IPO | 8.70% |
Recent News & Updates
Shareholder Returns
| 4183 | TW Medical Equipment | TW Market | |
|---|---|---|---|
| 7D | 3.6% | -0.3% | -1.0% |
| 1Y | -7.7% | -12.9% | -11.3% |
Return vs Industry: 4183 exceeded the TW Medical Equipment industry which returned -14.2% over the past year.
Return vs Market: 4183 exceeded the TW Market which returned -12.3% over the past year.
Price Volatility
| 4183 volatility | |
|---|---|
| 4183 Average Weekly Movement | 4.2% |
| Medical Equipment Industry Average Movement | 4.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.3% |
| 10% least volatile stocks in TW Market | 2.3% |
Stable Share Price: 4183 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: 4183's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 127 | n/a | https://epsbio.com |
EPS Bio Technology Corp. manufactures and sells OEM/ODM glucose meters and strips primarily in Taiwan. It also provides diabetic self-monitoring blood glucose systems under the EASYMAX and MDT2 BLE name, as well as wearable, and NFC and Bluetooth connectivity blood glucose monitors. The company is headquartered in Hsinchu City, Taiwan.
EPS Bio Technology Fundamentals Summary
| 4183 fundamental statistics | |
|---|---|
| Market Cap | NT$440.30m |
| Earnings (TTM) | NT$26.50m |
| Revenue (TTM) | NT$504.46m |
16.6x
P/E Ratio0.9x
P/S RatioIs 4183 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4183 income statement (TTM) | |
|---|---|
| Revenue | NT$504.46m |
| Cost of Revenue | NT$380.07m |
| Gross Profit | NT$124.39m |
| Other Expenses | NT$97.89m |
| Earnings | NT$26.50m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.11 |
| Gross Margin | 24.66% |
| Net Profit Margin | 5.25% |
| Debt/Equity Ratio | 5.8% |
How did 4183 perform over the long term?
See historical performance and comparisonDividends
6.5%
Current Dividend Yield106%
Payout RatioDoes 4183 pay a reliable dividends?
See 4183 dividend history and benchmarks| EPS Bio Technology dividend dates | |
|---|---|
| Ex Dividend Date | Jul 12 2022 |
| Dividend Pay Date | Aug 04 2022 |
| Days until Ex dividend | 14 days |
| Days until Dividend pay date | 37 days |
Does 4183 pay a reliable dividends?
See 4183 dividend history and benchmarksValuation
Is 4183 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4183?
Other financial metrics that can be useful for relative valuation.
| What is 4183's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | NT$440.30m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.7x |
| Enterprise Value/EBITDA | 6.8x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 4183's PE Ratio compare to its peers?
| 4183 PE Ratio vs Peers |
|---|
| Company | PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 19.8x | ||
6543 Perfect Medical Industry | 19x | n/a | NT$737.8m |
3373 Radiant Innovation | 20.2x | n/a | NT$1.0b |
4735 AViTA | 7.9x | n/a | NT$1.3b |
4129 United Orthopedic | 31.8x | n/a | NT$2.2b |
4183 EPS Bio Technology | 16.6x | n/a | NT$440.3m |
Price-To-Earnings vs Peers: 4183 is good value based on its Price-To-Earnings Ratio (16.6x) compared to the peer average (19.8x).
Price to Earnings Ratio vs Industry
How does 4183's PE Ratio compare vs other companies in the TW Medical Equipment Industry?
Price-To-Earnings vs Industry: 4183 is good value based on its Price-To-Earnings Ratio (16.6x) compared to the TW Medical Equipment industry average (20.1x)
Price to Earnings Ratio vs Fair Ratio
What is 4183's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 16.6x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 4183's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 4183 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4183 (NT$18.5) is trading below our estimate of fair value (NT$32.84)
Significantly Below Fair Value: 4183 is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 4183's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is EPS Bio Technology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
17.0%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as EPS Bio Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine whether EPS Bio Technology is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
Past Performance
How has EPS Bio Technology performed over the past 5 years?
Past Performance Score
5/6Past Performance Score 5/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
16.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4183 has high quality earnings.
Growing Profit Margin: 4183's current net profit margins (5.3%) are higher than last year (4.8%).
Past Earnings Growth Analysis
Earnings Trend: 4183's earnings have grown by 16.6% per year over the past 5 years.
Accelerating Growth: 4183's earnings growth over the past year (20.1%) exceeds its 5-year average (16.6% per year).
Earnings vs Industry: 4183 earnings growth over the past year (20.1%) exceeded the Medical Equipment industry 13.7%.
Return on Equity
High ROE: 4183's Return on Equity (8.8%) is considered low.
Discover strong past performing companies
Financial Health
How is EPS Bio Technology's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: 4183's short term assets (NT$405.1M) exceed its short term liabilities (NT$162.9M).
Long Term Liabilities: 4183's short term assets (NT$405.1M) exceed its long term liabilities (NT$120.3M).
Debt to Equity History and Analysis
Debt Level: 4183 has more cash than its total debt.
Reducing Debt: 4183's debt to equity ratio has reduced from 11.2% to 5.8% over the past 5 years.
Debt Coverage: 4183's debt is well covered by operating cash flow (307.6%).
Interest Coverage: 4183's interest payments on its debt are well covered by EBIT (16.8x coverage).
Balance Sheet
Discover healthy companies
Dividend
What is EPS Bio Technology current dividend yield, its reliability and sustainability?
Dividend Score
3/6Dividend Score 3/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
6.49%
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 4183's dividend (6.49%) is higher than the bottom 25% of dividend payers in the TW market (2.54%).
High Dividend: 4183's dividend (6.49%) is in the top 25% of dividend payers in the TW market (6.35%)
Stability and Growth of Payments
Stable Dividend: 4183's dividend payments have been volatile in the past 10 years.
Growing Dividend: 4183's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its high payout ratio (106.1%), 4183's dividend payments are not well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (69.5%), 4183's dividend payments are covered by cash flows.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
EPS Bio Technology has no CEO, or we have no data on them.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
EPS Bio Technology Corp.'s employee growth, exchange listings and data sources
Key Information
- Name: EPS Bio Technology Corp.
- Ticker: 4183
- Exchange: TPEX
- Founded: NaN
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: NT$440.300m
- Shares outstanding: 23.80m
- Website: https://epsbio.com
Number of Employees
Location
- EPS Bio Technology Corp.
- No. 8, R&D Road III
- Hsinchu Science Park
- Hsinchu City
- 30076
- Taiwan
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/06/27 00:00 |
| End of Day Share Price | 2022/06/27 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.